 SAN DIEGO, Sept. 08, 2021 GLOBE NEWSWIRE -- Turning Point Therapeutics, Inc. NASDAQ: TPTX, a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced a late-breaker abstract of early clinical data by physician assessment for repotrectinib in NTRK-positive TKI-naïve and TKI-pretreated advanced solid tumor cohorts of TRIDENT-1 has been accepted for oral presentation in a plenary session at the Virtual International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research AACR, the National Cancer Institute NCI and the European Organisation for Research and Treatment of Cancer EORTC on Oct. 7-10. 